Qilian International Holding Group Limited - Asset Resilience Ratio

Latest as of March 2025: 2.36%

Qilian International Holding Group Limited (BGM) has an Asset Resilience Ratio of 2.36% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check BGM strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$4.89 Million
Cash + Short-term Investments

Total Assets

$207.39 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how Qilian International Holding Group Limited's Asset Resilience Ratio has changed over time. See Qilian International Holding Group Limit (BGM) balance sheet quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Qilian International Holding Group Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Qilian International Holding Group Limit (BGM) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $4.89 Million 2.36%
Total Liquid Assets $4.89 Million 2.36%

Asset Resilience Insights

  • Limited Liquidity: Qilian International Holding Group Limited maintains only 2.36% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Qilian International Holding Group Limited Industry Peers by Asset Resilience Ratio

Compare Qilian International Holding Group Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Huadong Medicine Co Ltd
SHE:000963
Drug Manufacturers - Specialty & Generic 0.05%
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
Drug Manufacturers - Specialty & Generic -0.89%
Walvax BioTech
SHE:300142
Drug Manufacturers - Specialty & Generic 2.20%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
Drug Manufacturers - Specialty & Generic -2.56%
Celltrion Pharm Inc
KQ:068760
Drug Manufacturers - Specialty & Generic 12.49%
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
Drug Manufacturers - Specialty & Generic 0.40%

Annual Asset Resilience Ratio for Qilian International Holding Group Limited (2018–2024)

The table below shows the annual Asset Resilience Ratio data for Qilian International Holding Group Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-09-30 15.70% $8.32 Million $53.00 Million -13.45pp
2023-09-30 29.15% $14.94 Million $51.26 Million --
2022-09-30 0.00% $0.00 $64.53 Million --
2019-09-30 0.00% $0.00 $35.27 Million --
2018-09-30 0.04% $14.58K $33.34 Million --
pp = percentage points

About Qilian International Holding Group Limited

NASDAQ:BGM USA Drug Manufacturers - Specialty & Generic
Market Cap
$70.12 Million
Market Cap Rank
#20696 Global
#4616 in USA
Share Price
$0.39
Change (1 day)
-12.59%
52-Week Range
$0.26 - $13.12
All Time High
$58.32
About

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufactu… Read more